ArticleJournal of neuroinflammation2020
Increased serum neurofilament light chain concentration indicates poor outcome in Guillain-Barré syndrome.
Article in Journal of neuroinflammation, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 1 synthesis or guideline pooled it, 81 citations in OpenAlex.
- Types and Concentrations of Blood-Based Biomarkers in Adults With Peripheral Neuropathies: A Systematic Review and Meta-analysis.JAMA network open · 2022Pooled it
- Neurofilament light chain improves clinical prognostic models for Guillain-Barré syndrome.Journal of neurology, neurosurgery, and psychiatry · 2025Trial
- Results From a Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of ANX005, a C1q Inhibitor, in Patients With Guillain-Barré Syndrome.Journal of the peripheral nervous system : JPNS · 2025Trial
- Proteomic profile of CSF obtained at the time of diagnosis determines amyotrophic lateral sclerosis progression and survival: CXCL7 levels in disease prognosis and survival.Brain pathology (Zurich, Switzerland) · 2026Article
- Cerebrospinal fluid alpha-internexin concentrations measured in patients with Guillain-Barré syndrome: a possible prognostic biomarker for disability at 12 months.Journal of neurology · 2026Article
- Serum Galectin-3 as a biomarker in acute inflammatory polyradiculoneuropathies: a cohort study.Journal of neurology · 2026Article
- Guillain-Barré Syndrome: Progress in Diagnosis, Biomarkers, Neuroimaging and Management.ImmunoTargets and therapy · 2026Review
- Neurofilament Light Chain Levels as Diagnostic and Prognostic Biomarkers in Guillain-Barré Syndrome: An Updated Systematic Review and Meta-Analysis.Neurology and therapy · 2025Article
- Comparison of intravenous efgartigimod and intravenous immunoglobulin in patients with Guillain-Barré syndrome.Orphanet journal of rare diseases · 2025Article
- Protocol for a Prospective Cohort Study on Determinants of Outcomes in Lumbar Radiculopathy Surgery.Healthcare (Basel, Switzerland) · 2025Article
- Serum Neurofilament Light Chain as a Biomarker for CIDP Diagnosis, Severity, and Treatment Outcome.Neurology(R) neuroimmunology & neuroinflammation · 2025Article
- Exploring the Clinical Utility of Neurofilament Light Chain Assays in Multiple Sclerosis Management.Neurology(R) neuroimmunology & neuroinflammation · 2025Review
- Clinical use and reporting of neurofilament quantification in neurological disorders: A global overview.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Critical insights for intensivists on Guillain-Barré syndrome.Annals of intensive care · 2025Review
- Brain-Derived Tau as an Outcome Marker in Guillain-Barré Syndrome: A Retrospective Cohort Study.European journal of neurology · 2025Article
- Combined Exercise and Ursolic Acid Improve Hippocampal Neuronal Markers and Exploratory-Locomotor Behavior in Aged Diabetic Rats.Journal of aging research · 2025Article
- Serum neurofilament light chain predicts disease severity in axonal variants of acute immune neuropathies: A retrospective monocentric cohort study.European journal of neurology · 2025Article
- Neurofilament light chain as a diagnostic and prognostic biomarker in Guillain-Barré syndrome.Journal of neurology · 2024Article
- Serum neurofilament light chain levels correlate with small fiber related parameters in patients with hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN).Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2024Article
- Serum neurofilament light chain levels are associated with depression among US adults: a cross-sectional analysis among US adults, 2013-2014.BMC psychiatry · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGuillain-Barré syndrome (GBS) is an autoimmune disease that results in demyelination and axonal damage. Five percent of patients die and 20% remain significantly disabled on recovery. Recovery is slow in most cases and eventual disability is difficult to predict, especially early in the disease. Blood or cerebrospinal fluid (CSF) biomarkers that could help identify patients at risk of poor outcome are required. We measured serum neurofilament light chain (sNfL) concentrations from blood taken upon admission and investigated a correlation between sNfL and clinical outcome.
methodsBaseline sNfL levels in 27 GBS patients were compared with a control group of 22 patients with diagnoses not suggestive of any axonal damage. Clinical outcome parameters for GBS patients included (i) the Hughes Functional Score (HFS) at admission, nadir, and discharge; (ii) the number of days hospitalised; and (iii) whether intensive care was necessary.
resultsThe median sNfL concentration in our GBS sample on admission was 85.5 pg/ml versus 9.1 pg/ml in controls. A twofold increase in sNfL concentration at baseline was associated with an HFS increase of 0.6 at nadir and reduced the likelihood of discharge with favourable outcome by a factor of almost three. Higher sNfL levels upon admission correlated well with hospitalisation time (r
conclusionssNfL levels measured at hospital admission correlated with clinical outcome in GBS patients. These results represent amounts of acute axonal damage and reflect mechanisms resulting in disability in GBS. Thus, sNfL may serve as a convenient blood-borne biomarker to personalise patient care by identifying those at higher risk of poor outcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.